Smartphone-Based Acceptance and Commitment Therapy Aids Fibromyalgia
By Lori Solomon HealthDay Reporter
FRIDAY, Aug. 2, 2024 -- Digital acceptance and commitment therapy (ACT) is safe and efficacious compared with daily digital symptom tracking for managing fibromyalgia, according to a study published online July 8 in The Lancet.
R. Michael Gendreau, M.D., Ph.D., from Gendreau Consulting in Poway, California, and colleagues randomly assigned 275 adult participants (aged 22 to 75 years) with fibromyalgia to either the digital ACT group (12-week, self-guided, smartphone-delivered digital ACT program) or an active control group that offered daily symptom tracking and monitoring and access to health-related and fibromyalgia-related educational materials.
The researchers found that at 12 weeks, 71 percent of ACT participants reported improvement on the patient global impression of change versus 22 percent of the active control participants. There were no reports of device-related safety events.
"Fibromyalgia options are typically limited to a handful of pharmacological interventions that have limited efficacy and that can come with difficult-to-manage side effects," coauthor Mike Rosenbluth, Ph.D., CEO of Swing Therapeutics, said in a statement. "This publication validates Stanza as a guideline-directed nondrug approach that many patients previously couldn’t access due to few available trained clinicians, geographic limitations, and cost."
Swing Therapeutics funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.